首页> 外文期刊>Therapeutic innovation & regulatory science. >Bridging the Gap Between RCTs and RWE Through Endpoint Selection
【24h】

Bridging the Gap Between RCTs and RWE Through Endpoint Selection

机译:通过端点选择缩小RCT和RWE之间的差距

获取原文
获取原文并翻译 | 示例
           

摘要

This commentary is authored by several industry real-world evidence (RWE) experts, with support from IQVIA, as part of the 'RWE Leadership Forum': a group of Industry Leaders who have come together as non-competitive partners to understand and respond to RWD/E challenges and opportunities with a single expert voice. Here, the forum discusses the value in bridging the industry disconnect between RTCs and RWE, with a view to promoting the use of RWE in the RCT environment. RCT endpoints are explored along several axes including their clinical relevance and their measure of direct patient benefit, and then compared with their real-world counterparts to identify suitable paths, or gaps, for assimilating RWE endpoints into the RCT environment.
机译:本评论由几位行业真实世界证据(RWE)专家撰写,并得到IQVIA的支持,作为“RWE领导力论坛”的一部分:一群行业领袖以非竞争性合作伙伴的身份聚集在一起,以一个专家的声音理解和应对RWD/E的挑战和机遇。在这里,论坛讨论了在RTC和RWE之间弥合行业脱节的价值,以促进RWE在RCT环境中的使用。沿着几个轴探索RCT终点,包括它们的临床相关性和它们对患者直接利益的衡量,然后与现实世界中的对应者进行比较,以确定将RWE终点融入RCT环境的合适路径或差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号